

DIABESITY CME course 2022

September 16 and 17, 2022, Faculty of Medicine, Maribor, Slovenia

Starting on Friday, 16 september 2022 from 13:00 – 18:00; Saturday 17 september 2022, from 8:00 a.m. to 17.00).

(Sessions last 120 minutes; 20 minutes for lecture and 10 minutes for discussion)

PROGRAMME

FRIDAY, September 16, 2022

13:00 Participants registration

13:20-13:30 Welcome & introduction to the organizers

1st Session (13:30 -15:30)

BASIC RESEARCH

1	Renal lipotoxicity, from animal models to humans	Covadonga Rodríguez (Spain)
2	Animal model of Extreme obesity and renal disease	Maru Navarro (Spain)
3	Preclinical models of DKD	Liam Martin (Ireland)
4	Endothelial glycocalyx damage in diabetic nephropathy - a path to injury and/or a therapeutic target?	Ivo Laranjinha (Portugal)
	Open discussion	

Coffee break

2nd Session (16:00 - 18:00)

EPIDEMIOLOGY

1	Obesity and CKD	Radovan Hojs (Slovenia)
2	Link between NAFLD-NASH and CKD	Enrique Morales (Spain)
3	The impact of diabetes on cardiovascular mortality among persons with advanced CKD	Mads Hornum (Denmark)
4	Adiposity and the risk of glomerular decline	Trond Jenssen (Norway)
	Open discussion	

SATURDAY, September 17, 2022

3rd Session (08:00 - 10:00)

EVALUATION

1	Vascular stiffness in obese patients with CKD and diabetes	Robert Ekart (Slovenia)
2	Vascular damage in Diabetic Nephropathy The ENBiBA project	Esteban Porrini (Spain)
3	Crosstalk between bone and the vasculature in diabetes and CKD.	Maria Mace (Denmark)
4	Diet intervention in patients with CKD, obesity, metabolic syndrome or diabetes: effect on renal outcomes	Manuela Abbate (Spain)
	Open discussion	

Coffee break

4th Session (10:30 - 12:30)

DIAGNOSTIC

1	The non-invasive CV risk assessment of obese diabetic patients with CKD	Sebastjan Bevc (Slovenia)
2	The error of estimated GFR in Diabetes	Sergio Luis Lima (Spain)
3	NAFLD and CKD and challenges in diagnostic methods	Therese Adrian (Denmark)
4	Role of biomarkers in the early detection of kidney damage	Alberto Ortiz (Spain)
	Open discussion	

5th Session (12:30 - 14:00)

THERAPY

1	Mineralocorticoid receptor antagonists in DKD	Vodošek Hojs Nina (Slovenia)
2	SGLT2 inhibitors: a focus on CKD	Draženka Pongrac Barlovič (Slovenia)
3	Role of combination therapy in preventing DKD	Matias Trillini (Italy)
	Open discussion	

14:00 - 15:00 Lunch

6th Session (15:00 - 17:00) 12 min presentations

FUTURE PROSPECTIVE AND MISCELLANEOUS TOPIC OF OBESITY, DIABETES, CKD

1	Atherosclerosis, epigenetic modifications in CKD	Robert Ekart, Nejc Piko (Slovenia)
2	Renal proximal tubular epithelial cells: review of isolation, characterization, and culturing techniques	Bevc Sebastjan, Tadej Petreski, Luka Varda, Lidija Gradišnik, Uros Maver (Slovenia)
3	Caloric restriction reverses beta cell functional changes and glukose intolerance in a mouse of tpxe 2 diabetes	Maša Skelin Klemen, Lidija Križančič Bombek, Andraž Stožer (Slovenia)
5	Interleukin-1 Cytokines and kidney Injury in Diabetic Kidney Disease	Khaled Khazim (Israel)
6	CO-rebreathing and bioimpedance for measuring volume-changes in patients with CKD and diabetes treated with SGLT2 inhibitors	Tobias Bomholt (Denmark)
7	Hypomagnesemia and PTDM. Does it mean anything at all?	Rasmus Kirkeskov Carlsen (Norway)
8	New epigenetic insights related to high fat diet; a bridge between obesity and renal cancer. The Re.me.Diet study	Francesco Trevisani (Italy)
	Open discussion	

17:00 Conclusions